Stockreport

Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases

Sorrento Therapeutics, Inc.  (SRNE) 
Last sorrento therapeutics, inc. earnings: 8/9 04:49 pm Check Earnings Report
US:NASDAQ Investor Relations: sorrentotherapeutics.com/investors
PDF Two out of four patients showed complete resolution of liver metastases on PET scanMedian overall survival (OS) 8.3 months and mean OS 9.8 months, compared to the standa [Read more]